NCT06539559 2024-08-06Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast CancerCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Not yet recruiting60 enrolled
NCT03795012 2021-08-31Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer PatientsMedSIRPhase 2 Terminated22 enrolled
NCT00278993 2014-07-14Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior ChemotherapyEisai Inc.Phase 2 Completed108 enrolled 11 charts